StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a report published on Wednesday morning. The brokerage issued a sell rating on the stock.
Ayala Pharmaceuticals Price Performance
Shares of ADXS stock opened at $0.26 on Wednesday. The stock has a market capitalization of $2.82 million, a PE ratio of -0.03 and a beta of 1.45. Ayala Pharmaceuticals has a 52 week low of $0.14 and a 52 week high of $1.95. The firm has a 50 day moving average of $0.38 and a two-hundred day moving average of $0.59.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last announced its quarterly earnings data on Tuesday, April 16th. The company reported ($2.96) EPS for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Featured Articles
- Five stocks we like better than Ayala Pharmaceuticals
- What Does a Stock Split Mean?
- Sarepta Therapeutics Stock Soars on FDA Approval
- What Are Dividend Champions? How to Invest in the Champions
- CarMax: A Market Melt-Up Waiting to Happen for this Stock
- How to Use the MarketBeat Stock Screener
- 3 Solar Stocks to Watch that are Building the Green Energy Future
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
